Drugs / TY-302
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04433494 | Dec 2020 → May 2023 | breast cancer | TYK Medicines, Inc | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07104617 | Aug 2025 → Oct 2026 expected | prostate carcinoma | TYK Medicines, Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TY-302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07104617 ↗ |
| Route | Oral | “TY-302 is taken orally.” NCT04433494 ↗ |